GSK stock rocketed Wednesday after the pharma titan raised its 2031 sales outlook to north of $50 billion. Please watch the ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £23.55. The ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...